Versiones
- 18-12-2020 (5)
- 16-12-2020 (4)
Palabras clave
Bloqueo de inmunoglobulina E
Interferón
Omalizumab
Cómo citar
Plaudit
Resumen
El asma es una enfermedad inflamatoria crónica y heterogénea que afecta las vías respiratorias inferiores tanto de niños como de adultos. Los pacientes en quienes se han abordado factores modificables y continúan con episodios graves de asma aún después de la aplicación de dosis altas de corticosteroides se les diagnostica con asma grave; esta se asocia con mayor mortalidad y hospitalizaciones, así como con menor calidad de vida y mayores costos de atención médica. Se han identificado mecanismos inmunoinflamatorios tipo 2 altos, bajos y mixtos, en los cuales la inmunoglobulina E es un biomarcador prominente para el asma de inicio temprano y el asma de inicio tardío no alérgico. El bloqueo de la inmunoglobulina E disminuye indirectamente la expresión de su receptor de alta afinidad, disminuyendo la producción de citocinas tipo 2 e inhibiendo la inflamación eosinofílica, así como la modulación de la inflamación tipo 2. Por otro lado, la evidencia preclínica y clínica respalda la existencia de una estrecha contrarregulación de las vías del receptor de inmunoglobulina E de alta afinidad y del interferón, y un posible mecanismo de prevención de exacerbaciones inducidas por virus. La siguiente revisión resume la larga experiencia clínica del resultado de bloquear la inmunoglobulina E en el asma grave.Referencias
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. DOI: 10.3389/fped.2019.00246
Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469-478. DOI: 10.1111/j.1398-9995.2004.00526.x
To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. DOI: 10.1186/1471-2458-12-204
Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-360. DOI: 10.1016/j.jaci.2010.11.037
Thien F, Beggs PJ, Csutoros D, Darvall J, Hew M, Davies JM, et al. The Melbourne epidemic thunderstorm asthma event 2016: an investigation of environmental triggers, effect on health services, and patient risk factors. Lancet Planet Health. 2018;2(6):e255-e263. DOI: 10.1016/S2542-5196(18)30120-7
Achakulwisut P, Brauer M, Hystad P, Anenberg SC. Global, national, and urban burdens of paediatric asthma incidence attributable to ambient NO2 pollution: estimates from global datasets. Lancet Planet Health. 2019;3(4):e166-e178. DOI: 10.1016/S2542-5196(19)30046-4
Kim CK, Callaway Z, Gern JE. Viral infections and associated factors that promote acute exacerbations of asthma. Allergy Asthma Immunol Res. 2018;10:12-17. DOI: 10.4168/aair.2018.10.1.12
Custovic A, Belgrave D, Lin L, Bakhsoliani E, Telcian AG, Solari R, et al. Cytokine responses to rhinovirus and development of asthma, allergic sensitization, and respiratory infections during childhood. Am J Respir Crit Care Med. 2018;197(10):1265-1274. DOI: 10.1164/rccm.201708-1762OC
Helby J, Nordestgaard BG, Benfield T, Bojesen SE. Asthma, other atopic conditions and risk of infections in 105 519 general population never and ever smokers. J Intern Med. 2017;282(3):254-267. DOI: 10.1111/joim.12635
Custovic A, Ainsworth J, Arshad H, et al. The Study Team for Early Life Asthma Research (STELAR) consortium ‘Asthma e-lab’: team science bringing data, methods and investigators together. Thorax. 2015;70(8):799-801. DOI: 10.1136/thoraxjnl-2015-206781
Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet. 2017;390(10098):935-945. DOI: 10.1016/S0140-6736(17)31448-4
Global Strategy for Asthma Management and Prevention, 2019. EE. UU.: Global Initiative for Asthma; 2019.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-373. DOI: 10.1183/09031936.00202013. Errata en: Eur Respir J. 2014;43(4):1216. Correción del autor en: Eur Respir J. 2018;52(1):1352020.
Rajan S, Gogtay NJ, Konwar M, Thatte UM. The global initiative for asthma guidelines (2019): change in the recommendation for the management of mild asthma based on the SYGMA-2 trial - A critical appraisal. Lung India. 2020;37(2):169-173. DOI: 10.4103/lungindia.lungindia_308_19
Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99. DOI: 10.1164/rccm.200801-060ST
Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. DOI: 10.1016/j.jaci.2014.08.042
Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res. 2018;4(1):125-2017. DOI: 10.1183/23120541.00125-2017
Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649-1659. DOI: 10.1111/all.13771
Narendra D, Blixt J, Hanania NA. Immunological biomarkers in severe asthma. Semin Immunol. 2019;46:101332. DOI: 10.1016/j.smim.2019.101332
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45-56. DOI: 10.1038/ni.3049
Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015;192(6):660-668. DOI: 10.1164/rccm.201504-0763PP
Tan R, Liew MF, Lim HF, Leung BP, Fred-Wong WS. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020;179:114012. DOI: 10.1016/j.bcp.2020.114012
Fitzpatrick AM, Moore WC. Severe asthma phenotypes - how should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5(4):901-908. DOI: 10.1016/j.jaip.2017.05.015
Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219-233. DOI: 10.1007/s12016-018-8712-1
Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. DOI: 10.1183/13993003.00588-2019
Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Domingo C, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782. DOI: 10.1183/13993003.01782-2017
Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19(1):113. DOI: 10.1186/s12931-018-0813-0
Oishi K, Matsunaga K. Three-step algorithm for biological therapy targeted IgE and IL-5 in severe asthma. Immun Inflamm Dis. 2018;6(3):374-376. DOI: 10.1002/iid3.233
Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42. DOI: 10.1016/j.anai.2015.10.027
Domingo C. Overlapping effects of new monoclonal antibodies for severe asthma. Drugs. 2017;77(16):1769-1787. DOI: 10.1007/s40265-017-0810-5
Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: from bench to clinic - contribution of the discovery of interleukin-5. Cytokine. 2017;98:59-70. DOI: 10.1016/j.cyto.2016.11.011
Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med. 2012;6:27-40. DOI: 10.4137/CCRPM.S7793
Boushey HA. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol. 2001;108(2 Suppl):S77-S83. DOI: 10.1067/mai.2001.116434
Plosker GL, Keam SJ. Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs. 2008;22(3):189-204. DOI: 10.2165/00063030-200822030-00005
Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139(1):28-35. DOI: 10.1378/chest.10-1194
Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Ramos S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309-316. DOI: 10.1111/j.1398-9995.2004.00772.x
Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;1(2):254-261. DOI: 10.1183/09031936.01.00092101. Errata en: Eur Respir J. 2001;18(4):739-740.
Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008;102(10):1371-1378. DOI: 10.1016/j.rmed.2008.06.002
Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671-678. DOI: 10.1111/j.1398-9995.2010.02522.x
Kulus M, Hébert J, Garcia E, Fowler-Taylor A, Fernández-Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285-1293. DOI: 10.1185/03007991003771338
Humbert M, Berger W, Rapatz G, Turk F. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy. 2008;63(5):592-596. DOI: 10.1111/j.1398-9995.2008.01654.x
Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483-1492. DOI: 10.1016/j.rmed.2007.01.011
Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523. DOI: 10.1183/13993003.02523-2017
Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 20113;154(9):573-582. DOI: 10.7326/0003-4819-154-9-201105030-00002. Errata en: Ann Intern Med. 2019;171(7):528.
Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, et al. Retrospective study on the association of biomarkers with real-world outcomes of omalizumab-treated patients with allergic asthma. Clin Ther. 2019;41(10):1956-1971. DOI: 10.1016/j.clinthera.2019.07.021
Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo H, Peachey G, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223-2228. DOI: 10.1185/03007995.2011.620950
Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104(9):1381-1385. DOI: 10.1016/j.rmed.2010.06.001
Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015. DOI: 10.1056/NEJMoa1009705
Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476-1485. DOI: 10.1016/j.jaci.2015.09.008
Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709-717. DOI: 10.1111/j.1398-9995.2004.00550.x
Holgate ST, Chuchalin AG, Hébert J, Lötvall, Persson GB, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632-638. DOI: 10.1111/j.1365-2222.2004.1916.x
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. DOI: 10.1542/peds.108.2.e36
Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811. DOI: 10.1164/rccm.201208-1414OC
Annez 1. Summary of product characteristics [En línea]. Países Bajos: European Medicines Agency; 2020.
Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156-164.e1. DOI: 10.1016/j.jaip.2018.04.043
Canonica GW, Rottoli P, Bucca C, Zappa MC, Michetti G, Macciocchi B, et al. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organ J. 2018;11(1):33. DOI: 10.1186/s40413-018-0214-3
Bhutani M, Yang WH, Hébert J, de Takacsy F, Stril JL. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. PLoS One. 2017;12(8):e0183869. DOI: 10.1371/journal.pone.0183869
Barnes N, Menzies-Gow A, Mansur AH, Specner D, Percival F, Radwan A, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529-536. DOI: 10.3109/02770903.2013.790419
Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the “real-world” effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141-1151. DOI: 10.1016/j.rmed.2013.04.017
Zazzali JL, Raimundo KP, Trzaskoma B, Rosén KE, Schatz M. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc. 2015;36(4):283-292. DOI: 10.2500/aap.2015.36.3849
MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019;15(5):553-569. DOI: 10.1080/1744666X.2019.1574571
Deschildre A, Marguet C, Langlois C, Pin I, Rittié JL, Derelle J, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856-859. DOI: 10.1183/09031936.00008115
Licari A, Castagnoli R, Denicolò C, Rossini L, Seminara M, Sacchi L, et al. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13(1):36-42. DOI: 10.2174/1573398X13666170426094536
Sztafińska A, Jerzyńska J, Stelmach W, Woicka-Kolejwa K, Stelmach I. Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study. Postepy Dermatol Alergol. 2017;34(5):439-447. DOI: 10.5114/ada.2017.71109
Busse WW, Humbert M, Haselkorn T, Ortiz B, Trzsaskoma BL, Stephenson P, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2020;124(2):190-196. DOI: 10.1016/j.anai.2019.11.016
Sabogal-Piñeros YS, Bal SM, Dijkhuis A, Majoor CF, Dierdorp BS, Dekker T, et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019;74(10):1898-1909. DOI: 10.1111/all.13802
Hilvering B, Pavord ID. What goes up must come down: biomarkers and novel biologicals in severe asthma. Clin Exp Allergy. 2015;45(7):1162-1169. DOI: 10.1111/cea.12500
Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(6):1147-1154. DOI: 10.1016/j.jaci.2003.10.003
López-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Late breaking abstract - IgE-FceR1 cross-linking impairs the capacity of plasmacytoid dendritic cells to induce in vitro functional regulatory T cells which can be restored by omalizumab. Eur Respir J. 2019;54:OA3803. DOI: 10.1183/13993003.congress-2019.OA3803
Roth M, Zhao F, Zhong J, Lardinois D, Tamm M. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS One. 2015;10(9):e0136549. DOI: 10.1371/journal.pone.0136549
Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83(6):520-528. DOI: 10.1159/000334701
Riccio AM, Dal-Negro RW, Micheletto C, de Ferrari L, Folli C, Chiappori A, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25(2):475-484. DOI: 10.1177/039463201202500217
Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I, et al. IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418-1429. DOI: 10.1016/j.jaip.2019.02.030
Brito Rde C, da Silva GA, Motta ME, Brito MC. The association of rhinoconjunctivitis and asthma symptoms in adolescents. Rev Port Pneumol. 2009;15(4):613-628. DOI: 10.1016/S0873-2159(15)30160-4
Hong S, Son DK, Lim WR, Kim SH, Kim H, Kwon H, et al. The prevalence of atopic dermatitis, asthma, and allergic rhinitis and the comorbidity of allergic diseases in children. Environ Health Toxicol. 2012;27:e2012006. DOI: 10.5620/eht.2012.27.e2012006
Larsen K. The clinical relationship of nasal polyps to asthma. Allergy Asthma Proc. 1996;17(5):243-249. DOI: 10.2500/108854196778662255
Philpott CM, Erskine S, Hopkins C, Kumar N, Anari S, Kara N, Ray J, et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res. 2018;19(1):129. DOI: 10.1186/s12931-018-0823-y
Hill DA, Grundmeier RW, Ram G, Spergel JM. The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study. BMC Pediatr. 2016;16:133. DOI: 10.1186/s12887-016-0673-z
Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2(1):e185630. DOI: 10.1001/jamanetworkopen.2018.5630
Heck S, Al-Shobash S, Rapp D, Omlor A, Bekhit A, Flaig M, et al. High probability of comorbidities in bronchial asthma in Germany. NPJ Prim Care Respir Med. 2017;27(1):28. DOI: 10.1038/s41533-017-0026-x
Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Hew M, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384-1390. DOI: 10.1111/resp.12838
Jantunen J, Haahtela T, Salimäki J, et al. Multimorbidity in asthma, allergic conditions and COPD increase disease severity, drug use and costs: the Finnish pharmacy survey. Int Arch Allergy Immunol. 2019;179(4):273-280. DOI: 10.1159/000498861
Boulet LP, Boulay MÈ. Asthma-related comorbidities. Expert Rev Respir Med. 2011;5(3):377-393. DOI: 10.1586/ers.11.34
Colodenco D, Palomares O, Celis C, Kaplan A, Domingo C. Moving toward consensus on diagnosis and management of severe asthma in adults. Curr Med Res Opin. 2018;34(3):387-399. DOI: 10.1080/03007995.2017.1380617
Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86. DOI: 10.1097/ACI.0b013e32835c16b6
Adelroth E, Rak S, Haahtela T, Rosenhall L, Zetterstorm O, Byrne A, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106(2):253-259. DOI: 10.1067/mai.2000.108310
Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286(23):2956-2967. DOI: 10.1001/jama.286.23.2956
Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Shen H, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160-167. DOI: 10.1016/S1081-1206(10)62171-0
Masieri S, Cavaliere C, Begvarfaj E, Rosati D, Minni A. Effects of omalizumab therapy on allergic rhinitis: a pilot study. Eur Rev Med Pharmacol Sci. 2016;20(24):5249-5255.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271-279. DOI: 10.1111/j.1365-2222.2008.03121.x
Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, et al. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012;40(5):306-315. DOI: 10.1016/j.aller.2011.09.011
de Klerk TA, Sharma V, Arkwright PD, Biswas S. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS. 2013;17(3):305-306. DOI: 10.1016/j.jaapos.2012.12.153
Doan S, Amat F, Gabison E, Saf S, Cochereau I, Just J. Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature. Ophthalmol Ther. 2017;6(1):195-206. DOI: 10.1007/s40123-016-0074-2
Gevaert P, Calus L, van Zele T, Blomme K, de Ruyck N, Bachert C, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116.e1. DOI: 10.1016/j.jaci.2012.07.047
Vennera MC, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824-825. DOI: 10.1136/thx.2010.152835
Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21(4):428-432. DOI: 10.2500/ajr.2007.21.3060
Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89-93. DOI: 10.1159/000350486
Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29(5):530-537. DOI: 10.2500/aap.2008.29.3160
Li JX, Fan LC, Li MH, Cao WJ, Xu JF. Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature. Respir Med. 2017;122:33-42. DOI: 10.1016/j.rmed.2016.11.019
Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85-94. DOI: 10.1016/S2468-1253(17)30392-8
Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103-1110.e11. DOI: 10.1016/j.jaci.2015.10.005
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368-1374. DOI: 10.1016/j.jaci.2013.09.046
Namazy JA, Blais L, Andrews EB, Scheuerle AE, Cabana MD, Thorp JM, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145(2):528-536.e1. DOI: 10.1016/j.jaci.2019.05.019
Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788-797. DOI: 10.1111/j.1365-2222.2009.03214.x
Busse W, Buhl R, Fernandez-Vidaurre C, Blogg M, Zhu J, Eisner MD, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983-989.e6. DOI: 10.1016/j.jaci.2012.01.033
Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560-567.e4. DOI: 10.1016/j.jaci.2014.02.007
Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4(4):565-572. DOI: 10.1016/j.jaip.2016.04.012
Chung JH, Lee YJ, Kang TW, Kim KR, Jang DP, Kim IY, et al. Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol. 2015;124(8):663-670. DOI: 10.1177/0003489415576181
Fokkens W, Lund V, Mullol J; European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;20:1-136.
Johansson L, Akerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol. 2003;112(7):625-629. DOI: 10.1177/000348940311200709
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;50(23):3-298.
We J, Lee WH, Tan KL, Wee JH, Rhee CS, Lee CH, et al. Prevalence of nasal polyps and its risk factors: Korean National Health and Nutrition Examination Survey 2009-2011. Am J Rhinol Allergy. 2015;29(1):e24-e28. DOI: 10.2500/ajra.2015.29.4131
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3):470-477. DOI: 10.1183/09031936.03.00261903
Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405-413. DOI: 10.1016/j.jaci.2006.11.639
Haselkorn T, Borish L, Miller DP, Weiss ST, Wong DA. High prevalence of skin test positivity in severe or difficult-to-treat asthma. J Asthma. 2006;43(10):745-752. DOI: 10.1080/02770900601031540
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. DOI: 10.1111/all.13397
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Canonica GW, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-330. DOI: 10.1111/j.1398-9995.2010.02496.x
Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160. DOI: 10.1111/j.1398-9995.2007.01620.x
Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8(1):e7. DOI: 10.5415/apallergy.2018.8.e7
Patel N, Herbert L, Green TD. The emotional, social, and financial burden of food allergies on children and their families. Allergy Asthma Proc. 2017;38(2):88-91. DOI: 10.2500/aap.2017.38.4028
Chafen JJ, Newberry SJ, Riedl MA, Bravata DM, Maglione M, Suttorp MJ, et al. Diagnosing and managing common food allergies: a systematic review. JAMA. 2010;303(18):1848-1856. DOI: 10.1001/jama.2010.582
Loh W, Tang MLK. The epidemiology of food allergy in the global context. Int J Environ Res Public Health. 2018;15(9):2043. DOI: 10.3390/ijerph15092043
Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient’s perspective: a survey in five European countries. Patient. 2015;8(6):551-558. DOI: 10.1007/s40271-015-0145-9
Mendelson MH, Bernstein JA, Gabriel S, Balp MM, Tian H, Vietri J, et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatolog Treat. 2017;28(3):229-236. DOI: 10.1080/09546634.2016.1227421
Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115(4):306-311. DOI: 10.1016/j.anai.2015.06.030
Johnston DT, Sher L, Fineman SM, Zawadski R, Rosén K, Siri DD, et al. Prevalence of comorbities with peanut allergy: results from a phase 3, randomized, double-blind, placebo-controlled trial (PALISADE). J Allergy Clin Immunol. 2019;143(2):AB270. DOI: 10.1016/j.jaci.2018.12.824
Zhang N, Gevaert P, van Zele T, et al. An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis. Rhinology. 2005;43(3):162-168.
Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627. DOI: 10.3389/fimmu.2019.00627
Vashisht P, Casale T. Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther. 2013;13(6):933-945. DOI: 10.1517/14712598.2013.795943
Anvari S, Miller J, Yeh CY, Davis CM. IgE-mediated food allergy. Clin Rev Allergy Immunol. 2019;57(2):244-260. DOI: 10.1007/s12016-018-8710-3
Prescribing information [En línea]. EE. UU.: Food and Drug Administration; 2020. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103976s5224lbl.pdf
Burte E, Bousquet J, Siroux V, et al. The sensitization pattern differs according to rhinitis and asthma multimorbidity in adults: the EGEA study. Clin Exp Allergy. 2017;47(4):520-529. DOI: 10.1111/cea.12897
Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519-533. DOI: 10.1111/all.13083
A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps (POLYP 1) [En línea]. EE. UU.: National Institutes of Health; 2020. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03280550
A clinical trial of omalizumab in participants with chronic rhinosinusituswith nasal polyps (POLYP 2) [En línea]. EE. UU.: National Institutes of Health; 2020. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03280537 [accessed January 2020]
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies [En línea]. EE. UU.: Novartis; 2019.
Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750.e4. DOI: 10.1016/j.jaci.2015.12.1342
Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Abraham I, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019;155(1):29-38. DOI: 10.1001/jamadermatol.2018.3447
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134-140. DOI: 10.1016/j.jaci.2005.09.036
Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Leupold W, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274-280. DOI: 10.1067/mai.2002.121949
Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55(4):379-386. DOI: 10.2332/allergolint.55.379
Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol. 2009;149(3):239-245. DOI: 10.1159/000199719
Nagakura T, Ogino S, Okubo K, Sato N, Takahashi M, Ishikawa T. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy. 2008;38(2):329-337. DOI: 10.1111/j.1365-2222.2007.02894.x
Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196-208. DOI: 10.1177/1945892419884774
Study of efficacy and safety of omalizumab in severe Japanese cedar pollinosis adult and adolescent patients [En línea]. EE. UU.: National Institutes of Health; 2020. Disponible en: https://clinicaltrials.gov/ct2/show/NCT03369704
Takahashi M, Soejima K, Taniuchi S, Hatano Y, Yamanouchi S, Ishikawa H, et al. Oral immunotherapy combined with omalizumab for high-risk cow’s milk allergy: a randomized controlled trial. Sci Rep. 2017;7(1):17453. DOI: 10.1038/s41598-017-16730-6. Errata en: Sci Rep. 2018;21(1):12812.
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873-881.e8. DOI: 10.1016/j.jaci.2016.08.010
Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309-1310.e1. DOI: 10.1016/j.jaci.2011.01.051
Vickery BP. Can omalizumab monotherapy benefit real-world food allergy patients? Lessons from an observational study. J Allergy Clin Immunol Pract. 2019;7(6):1910-1911. DOI: 10.1016/j.jaip.2019.05.007
Información para prescribir Xolair® (omalizumab) [En línea]. EE. UU.: Genentech USA, Inc./Novartis Pharmaceuticals Corporation. Disponible en: https://www.xolairhcp.com
Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol. 2016;138(3):913-915.e2. DOI: 10.1016/j.jaci.2016.03.030
Kim HL, Leigh R, Becker A. Omalizumab: practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol. 2010;6(1):32. DOI: 10.1186/1710-1492-6-32
Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study. Postgrad Med. 2017;129(6):598-604. DOI: 10.1080/00325481.2017.1321945)
Probst M, Gogolka A, Krüll M, Noga O. In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma. Allergol Select. 2019;2(1):49-55. DOI: 10.5414/ALX01377E
Solidoro P, Patrucco F, de Blasio F, Brussino L, Dassetto D, Pivetta E, et al. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Ther Adv Respir Dis. 2019;13:1753466619841274. DOI: 10.1177/1753466619841274
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190. DOI: 10.1067/mai.2001.117880
Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002;20(5):1088-1094. DOI: 10.1183/09031936.02.00016502
Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87-90.
Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti- immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004 Jul;59(7):701-708.
Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302-308. DOI: 10.1111/j.1398-9995.2004.00770.x
Chipps B, Buhl R, Beeh KM, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006;22(11):2201-2208. DOI: 10.1185/030079906X148643
Niebauer K, Dewilde S, Fox-Rushby J, Revicki DA. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2006;96(2):316-326. DOI: 10.1016/S1081-1206(10)61242-2
Niven R, McBryan D. A UK survey of oral corticosteroid use in patients treated with omalizumab. Thorax. 2007;62(3):A98. Abstract P91
Wu F, Takaro TK. Childhood asthma and environmental interventions. Environ Health Perspect. 2007;115(6):971-975. DOI: 10.1289/ehp.8989
Lanier BQ, Nayak A. Prevalence and impact of nighttime symptoms in adults and children with asthma: a survey. Postgrad Med. 2008;120(4):58-66. DOI: 10.3810/pgm.2008.11.1939
Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009;103(11):1633-1642. DOI: 10.1016/j.rmed.2009.06.014
Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G. Severe asthma and the omalizumab option. Clin Mol Allergy. 2008;6:4. DOI: 10.1186/1476-7961-6-4
Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104(10):1410-1416. DOI: 10.1016/j.rmed.2010.04.013
Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105(4):313-319. DOI: 10.1016/j.anai.2010.07.007
Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671-678. DOI: 10.1111/j.1398-9995.2010.02522.x
Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573-582. DOI: 10.7326/0003-4819-154-9-201105030-00002. Erratum in: Ann Intern Med. 2019;171(7):528.
Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015. DOI: 10.1056/NEJMoa1009705
Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012;6(4):215-227. DOI: 10.1111/j.1752-699X.2011.00263.x
Wilson SR, Rand CS, Cabana MD, Foggs MB, Halterman JS, Olson L, et al. Asthma outcomes: quality of life. J Allergy Clin Immunol. 2012;129(3 Suppl):S88-S123. DOI: 10.1016/j.jaci.2011.12.988
Lafeuille MH, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P. Association between consistent omalizumab treatment and asthma control. J Allergy Clin Immunol Pract. 2013;1(1):51-57. DOI: 10.1016/j.jaip.2012.08.006
Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224-1233. DOI: 10.1183/09031936.00149812
Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015 Feb;135(2):407-412. DOI: 10.1016/j.jaci.2014.08.025
Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476-1485. DOI: 10.1016/j.jaci.2015.09.008. Epub 2015 Oct 27. PMID: 26518090; PMCID: PMC4679705.
Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, et al. A randomized multicenter study Evaluating Xolair Persistence Of Response after long-Term therapy. J Allergy Clin Immunol. 2017;140(1):162-169.e2. DOI: 10.1016/j.jaci.2016.08.054
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2020 Revista Alergia México